TN2011000459A1 - Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases - Google Patents
Vaccine compositions and methods for treatment of mucormycosis and other fungal diseasesInfo
- Publication number
- TN2011000459A1 TN2011000459A1 TN2011000459A TN2011000459A TN2011000459A1 TN 2011000459 A1 TN2011000459 A1 TN 2011000459A1 TN 2011000459 A TN2011000459 A TN 2011000459A TN 2011000459 A TN2011000459 A TN 2011000459A TN 2011000459 A1 TN2011000459 A1 TN 2011000459A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methods
- vaccine compositions
- mucormycosis
- compositions
- ftr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16161409P | 2009-03-19 | 2009-03-19 | |
PCT/US2010/000820 WO2010107500A1 (fr) | 2009-03-19 | 2010-03-19 | Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2011000459A1 true TN2011000459A1 (en) | 2013-03-27 |
Family
ID=42739922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TN2011000459A TN2011000459A1 (en) | 2009-03-19 | 2011-09-09 | Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases |
Country Status (16)
Country | Link |
---|---|
US (2) | US20120093828A1 (fr) |
EP (1) | EP2408804A4 (fr) |
JP (1) | JP2012520878A (fr) |
KR (1) | KR20110139743A (fr) |
CN (1) | CN102639557A (fr) |
AU (1) | AU2010226320A1 (fr) |
CA (1) | CA2755273A1 (fr) |
CL (1) | CL2011002284A1 (fr) |
IL (1) | IL215093A0 (fr) |
MA (1) | MA33199B1 (fr) |
MX (1) | MX2011009735A (fr) |
NZ (2) | NZ614255A (fr) |
RU (1) | RU2011142173A (fr) |
SG (1) | SG174413A1 (fr) |
TN (1) | TN2011000459A1 (fr) |
WO (1) | WO2010107500A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1403092B1 (it) * | 2010-12-01 | 2013-10-04 | Univ Degli Studi Modena E Reggio Emilia | Metodo per la diagnosi e/o il monitoraggio della mucormicosi. |
EP2755681B1 (fr) | 2011-09-15 | 2018-06-27 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | IMMUNOTHÉRAPIE ET DIAGNOSTIC DE LA MUCORMYCOSE AU MOYEN DE CotH |
US20160017293A1 (en) * | 2012-08-15 | 2016-01-21 | Neostem Oncology, Llc | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same |
CN106590685A (zh) * | 2015-10-19 | 2017-04-26 | 粮华生物科技(北京)有限公司 | 重金属污染土壤的原位生物修复制剂和修复方法 |
WO2020006438A1 (fr) * | 2018-06-29 | 2020-01-02 | University Of Maryland, Baltimore | Méthodes de traitement ou de prévention de la mucormycose |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100380A (en) * | 1991-10-28 | 2000-08-08 | Cytran, Inc. | Immunomodulating peptides and methods of use |
PH31594A (en) | 1993-09-30 | 1998-11-03 | Janssen Pharmaceutica Nv | Oral formulations on an antifungal. |
TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
DE50111949D1 (de) * | 2000-12-16 | 2007-03-15 | Alstom Technology Ltd | Komponente einer Strömungsmaschine |
BR0206312A (pt) * | 2001-01-04 | 2004-02-17 | Univ Saskatchewan | Composição de vacina, uso sobrenadante de cultura celular de escherichia coli enteroemorrágica (ehec), e, métodos para a geração de uma resposta imunológica em um mamìfero contra um antìgeno de escherichia coli enteroemorrágica (ehec) secretado, e 0157:h7 enteroemorrágica (ehec 0157:h7) secretado, e para a redução da colonização de escherichia coli enteroemorrágica (ehec) em um ruminante |
US7363166B2 (en) * | 2001-03-30 | 2008-04-22 | Council Of Scientific & Industrial Research | Computational method for the identification of candidate proteins useful as anti-infectives |
WO2003018051A1 (fr) * | 2001-08-27 | 2003-03-06 | Vic Jira | Composition antifongique |
GB0223978D0 (en) | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
ITMI20022447A1 (it) | 2002-11-19 | 2004-05-20 | Carlo Ghisalberti | Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate. |
MXPA05007156A (es) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics | Formulacion farmaceuticas aerosolizable para terapia para infecciones fungicas. |
US7226600B2 (en) * | 2003-06-11 | 2007-06-05 | Ultra Biotech Limited | Method to prepare compositions comprising yeast treated with electromagnetic energy |
CA2550927A1 (fr) * | 2003-12-23 | 2005-07-14 | Glaxosmithkline Biologicals S.A. | Bacterie gram-negative comportant un niveau de lps reduit dans la membrane externe et utilisation de celle-ci pour traiter une infection bacterienne gram-negative |
US7588931B2 (en) * | 2004-11-04 | 2009-09-15 | E. I. Du Pont De Nemours And Company | High arachidonic acid producing strains of Yarrowia lipolytica |
EP2221382A3 (fr) * | 2006-03-24 | 2010-12-01 | BASF Plant Science GmbH | Protéines associées à une réponse au stress abiotique et homologues |
CL2007002026A1 (es) * | 2006-07-13 | 2008-06-06 | Los Angeles Biomed Res Inst | Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica. |
-
2010
- 2010-03-19 CN CN2010800212819A patent/CN102639557A/zh active Pending
- 2010-03-19 KR KR1020117024522A patent/KR20110139743A/ko not_active Application Discontinuation
- 2010-03-19 AU AU2010226320A patent/AU2010226320A1/en not_active Abandoned
- 2010-03-19 MX MX2011009735A patent/MX2011009735A/es active IP Right Grant
- 2010-03-19 MA MA34256A patent/MA33199B1/fr unknown
- 2010-03-19 US US13/257,585 patent/US20120093828A1/en not_active Abandoned
- 2010-03-19 CA CA2755273A patent/CA2755273A1/fr not_active Abandoned
- 2010-03-19 WO PCT/US2010/000820 patent/WO2010107500A1/fr active Application Filing
- 2010-03-19 JP JP2012500790A patent/JP2012520878A/ja active Pending
- 2010-03-19 SG SG2011066602A patent/SG174413A1/en unknown
- 2010-03-19 NZ NZ61425510A patent/NZ614255A/en not_active IP Right Cessation
- 2010-03-19 EP EP10753820A patent/EP2408804A4/fr not_active Withdrawn
- 2010-03-19 US US12/661,609 patent/US8444985B2/en not_active Expired - Fee Related
- 2010-03-19 NZ NZ595271A patent/NZ595271A/xx not_active IP Right Cessation
- 2010-03-19 RU RU2011142173/10A patent/RU2011142173A/ru not_active Application Discontinuation
-
2011
- 2011-09-09 TN TN2011000459A patent/TN2011000459A1/fr unknown
- 2011-09-11 IL IL215093A patent/IL215093A0/en unknown
- 2011-09-15 CL CL2011002284A patent/CL2011002284A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2408804A4 (fr) | 2012-10-03 |
CA2755273A1 (fr) | 2010-09-23 |
MA33199B1 (fr) | 2012-04-02 |
MX2011009735A (es) | 2011-10-19 |
EP2408804A1 (fr) | 2012-01-25 |
NZ614255A (en) | 2015-03-27 |
US8444985B2 (en) | 2013-05-21 |
KR20110139743A (ko) | 2011-12-29 |
WO2010107500A1 (fr) | 2010-09-23 |
US20120093828A1 (en) | 2012-04-19 |
SG174413A1 (en) | 2011-10-28 |
AU2010226320A1 (en) | 2011-10-13 |
CN102639557A (zh) | 2012-08-15 |
JP2012520878A (ja) | 2012-09-10 |
NZ595271A (en) | 2013-08-30 |
IL215093A0 (en) | 2011-11-30 |
RU2011142173A (ru) | 2013-04-27 |
US20100285024A1 (en) | 2010-11-11 |
CL2011002284A1 (es) | 2012-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ607996A (en) | Substituted nucleotide analogs | |
MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
NZ603901A (en) | Vectors and sequences for the treatment of diseases | |
MX2010005651A (es) | Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento. | |
NZ629427A (en) | Methods and compositions for treating huntington’s disease | |
MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
MX342326B (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. | |
TN2012000555A1 (en) | Antibodies to human gdf8 | |
IN2014CN03465A (fr) | ||
TN2011000459A1 (en) | Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases | |
MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
NZ594480A (en) | Methods and compositions for diagnosis and treatment of cancer | |
WO2005112636A3 (fr) | Compositions et procedes d'inhibition par arnic de genes du virus du polyome primate | |
ATE424208T1 (de) | Proteinkinaseinhibitoren | |
MX336711B (es) | Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos. | |
MX2022015169A (es) | Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos. | |
EA201890878A1 (ru) | Способ лечения медуллобластомы с помощью ингибитора ezh2 | |
MX2021006784A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos. | |
MX2021014465A (es) | Construcciones de arni para inhibir la expresion de scap y metodos de uso de las mismas. | |
NZ594347A (en) | Antibodies against human tweak and uses thereof | |
MX2023001786A (es) | Construcciones de iarn y metodos para inhibir la expresion de marc1. |